Table 3 Susceptibility of strains of S epidermidis to four fluoroquinolones
| No of isolates with the following MIC (μg/ml) | MIC50 | MIC90 | |||||||||||
| 0.025 | 0.05 | 0.1 | 0.2 | 0.39 | 0.78 | 1.56 | 3.13 | 6.25 | 12.5 | 25 | |||
| All isolates (n = 138) | |||||||||||||
| LVFX | 26 | 55 | 4 | 23 | 19 | 7 | 3 | 1 | 0.2 | 3.13 | |||
| GFLX | 29 | 52 | 4 | 1 | 24 | 24 | 2 | 1 | 1 | 0.1 | 1.56 | ||
| MFLX | 1 | 72 | 9 | 3 | 26 | 16 | 7 | 3 | 1 | 0.05 | 0.78 | ||
| TFLX | 35 | 47 | 3 | 2 | 21 | 10 | 10 | 8 | 2 | 0.05 | 3.13 | ||
| Mode | |||||||||||||
| Wild type (n = 68) | |||||||||||||
| LVFX | 24 | 44 | 0.2 | ||||||||||
| GFLX | 26 | 42 | 0.1 | ||||||||||
| MFLX | 1 | 60 | 7 | 0.05 | |||||||||
| TFLX | 30 | 38 | 0.05 | ||||||||||
| Mode | |||||||||||||
| Mutations in parC and/or parE (n = 17) | |||||||||||||
| LVFX | 1 | 11 | 4 | 1 | 0.2 | ||||||||
| GFLX | 2 | 10 | 4 | 1 | 0.1 | ||||||||
| MFLX | 11 | 2 | 3 | 1 | 0.05 | ||||||||
| TFLX | 4 | 9 | 3 | 1 | 0.05 | ||||||||
| Mode | |||||||||||||
| Mutations in both gyrA and ParC (n = 53) | |||||||||||||
| LVFX | 1 | 23 | 18 | 7 | 3 | 1 | 1.56 | ||||||
| GFLX | 1 | 1 | 24 | 23 | 2 | 1 | 1 | 0.78 | |||||
| MFLX | 1 | 26 | 15 | 7 | 3 | 1 | 0.39 | ||||||
| TFLX | 1 | 2 | 20 | 10 | 10 | 8 | 2 | 0.78 | |||||
-
GFLX, gatifloxacin; LVFX, levofloxacin; MFLX, moxifloxacin; TFLX, tosufloxacin.
